Slingshot members are tracking this event:

European Commission Approves Celgene's (CELG) REVLIMID for the Maintenance Treatment of Adult Patients with Newly Diagnosed Multiple Myeloma Who Have Undergone an Autologous Stem Cell Transplant

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords European Commission, Revlimid, Newly Diagnosed, Multiple Myeloma, Expanded Use, Autologous Stem Cell Transplant